Electra CEO reports 759K-share stock option
Electra Therapeutics’ CEO discloses existing option grants and Series A preferred stock that will convert into common shares at the IPO closing.
Rhea-AI Filing Summary
Electra Therapeutics, Inc. (ETRA) reports the initial beneficial ownership of its President and CEO, Dong Quehuong (Kathy), consisting of multiple employee stock options and shares of Series A Convertible Preferred Stock, each convertible into common stock. The options cover several blocks of common shares with exercise prices ranging from $4.40 to $15.00 per share and expirations between March 23, 2032 and September 16, 2036, subject to detailed time-based vesting schedules and, for several grants, early exercisability with the issuer’s right of repurchase. The Series A Convertible Preferred Stock represents 455,484 underlying common shares that will automatically convert into common stock upon the closing of the company’s initial public offering, with 73,147 of those underlying shares identified as restricted shares subject to monthly vesting beginning September 16, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Dong Quehuong (Kathy)
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F5 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F6 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F7 | -- | -- | -- |
| holding | Series A Convertible Preferred Stock F8, F9 | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 2,298,219 contracts (Direct);
Series A Convertible Preferred Stock — 455,484 contracts (Direct)
Footnotes (9)
- F1. 1/4th of the total shares subject to this option vested one year after March 24, 2022, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F2. 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F3. 1/4th of the total shares subject to this option vested one year after May 8, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F4. 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F5. 1/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.
- F6. The shares subject to this option are fully vested upon the date of grant.
- F7. 1/13th of the total shares subject to this option shall vest monthly commencing from September 16, 2026.
- F8. Each share of Series A Convertible Preferred Stock (the "Preferred Stock") will automatically convert into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
- F9. 73,147 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/13th of the Restricted Shares shall vest monthly commencing from September 16, 2026.
Key Figures
Option exercise price: $5.23 per share
Option exercise price: $4.40 per share
Option exercise price: $4.96 per share
+4 more
7 metrics
Option exercise price
$5.23 per share
Employee stock option over 59,086 underlying common shares expiring March 23, 2032
Option exercise price
$4.40 per share
Employee stock option over 281,987 underlying common shares expiring November 16, 2033
Option exercise price
$4.96 per share
Employee stock option over 70,903 underlying common shares expiring November 12, 2035
Largest option block
759,198 underlying shares
Employee stock option at $4.96 per share expiring February 12, 2036
Higher-price options
$15.00 per share
Employee stock options over blocks of 927,155, 167,798 and 32,092 underlying shares expiring September 16, 2036
Convertible preferred underlying common
455,484 shares
Common shares underlying Series A Convertible Preferred Stock that convert automatically at IPO closing
Restricted Shares
73,147 shares
Portion of common shares underlying the preferred stock vesting monthly in one-thirteenths from September 16, 2026
Key Terms
early exercisable, right of repurchase, Series A Convertible Preferred Stock, Restricted Shares, +1 more
5 terms
early exercisable financial
"The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase"
right of repurchase financial
"The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase"
Series A Convertible Preferred Stock financial
"Each share of Series A Convertible Preferred Stock will automatically convert into 1 share of Common Stock"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
initial public offering financial
"will automatically convert into 1 share of Common Stock upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing report for Electra Therapeutics (ETRA)?
It reports that President and CEO Dong Quehuong (Kathy) holds several employee stock options and Series A Convertible Preferred Stock in Electra Therapeutics, Inc., all referenced as of September 18, 2026, without any new purchases or sales disclosed.
What stock options does the CEO of ETRA hold and at what exercise prices?
The CEO holds employee stock options over blocks of Electra Therapeutics common stock with exercise prices of $5.23, $4.40, $4.96, and $15.00 per share, each with its own expiration date between 2032 and 2036 and time-based vesting schedules.
Are any of the CEO’s ETRA stock options early exercisable?
Yes. Several employee stock option grants are described as early exercisable, with the shares subject to the issuer’s right of repurchase. These options also feature vesting such as one-quarter after a year from specific grant-related dates and the remainder monthly thereafter.
What are the key vesting terms for the CEO’s ETRA equity awards?
Some option grants vest one-quarter after one year from dates such as March 24, 2022, October 16, 2023, or May 8, 2025, then monthly in forty-eightths, while others vest monthly from February 1, 2026 or September 17, 2026. One option grant is fully vested on the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
